lanadelumab

Shire Secures FDA Approval for HAE Drug Lanadelumab
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Flag link:
Shire dodges pricing questions as lanadelumab’s big day nears
Shire dodges pricing questions as lanadelumab’s big day nears
EP Vantage
Takeda
HAE
lanadelumab
FDA
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Shire's HAE candidate boosted by new Phase 3 data
Shire's HAE candidate boosted by new Phase 3 data
Biopharma Dive
Shire
HAE
clinical trials
lanadelumab
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Seeking Alpha
Shire
HAE
SHP643
lanadelumab
Flag link:
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Shire
lanadelumab
DX-2930
HAE
Cinryze
Dyax
Flag link:
Shire Rises on Encouraging Angioedema Results
Shire Rises on Encouraging Angioedema Results
TheStreet.com
Shire
angioedema
lanadelumab
Flag link: